VolitionRx Limited (VNRX) 10-Q14 Aug 242024 Q2 Quarterly reportFinancial data

Company Profile

Cover

Cover - shares	6 Months Ended
Cover - shares	Jun. 30, 2024	Aug. 13, 2024
Cover [Abstract]
Entity Registrant Name	VolitionRx Limited
Entity Central Index Key	0000093314
Document Type	10-Q
Amendment Flag	false
Current Fiscal Year End Date	--12-31
Entity Small Business	true
Entity Shell Company	false
Entity Emerging Growth Company	false
Entity Current Reporting Status	Yes
Document Period End Date	Jun. 30, 2024
Entity Filer Category	Non-accelerated Filer
Document Fiscal Period Focus	Q2
Document Fiscal Year Focus	2024
Entity Common Stock Shares Outstanding		92,101,479
Entity File Number	001-36833
Entity Incorporation State Country Code	DE
Entity Tax Identification Number	91-1949078
Entity Address Address Line 1	1489 West Warm Springs Road
Entity Address Address Line 2	Suite 110
Entity Address City Or Town	Henderson
Entity Address State Or Province	NV
Entity Address Postal Zip Code	89014
City Area Code	646
Local Phone Number	650–1351
Security 12b Title	Common Stock, par value $0.001 per share
Trading Symbol	VNRX
Security Exchange Name	NYSE
Document Quarterly Report	true
Document Transition Report	false
Entity Interactive Data Current	Yes

Condensed Consolidated Balance

Condensed Consolidated Balance Sheets - USD ($)	Jun. 30, 2024	Dec. 31, 2023
Current Assets
Cash and cash equivalents	$ 5,998,928	$ 20,729,983
Accounts receivable	166,262	242,617
Prepaid expenses	828,965	521,370
Other current assets	350,927	360,125
Total Current Assets	7,345,082	21,854,095
Property and equipment, net	4,878,417	5,523,013
Operating lease right-of-use assets	512,317	549,504
Intangible assets, net	332,221	23,886
Total Assets	13,068,037	27,950,498
Current Liabilities
Accounts payable	3,348,322	3,211,287
Accrued liabilities	3,227,595	3,928,761
Deferred revenue	22,938,400	23,000,000
Management and directors' fees payable	25,073	59,625
Current portion of long-term debt	1,043,142	1,207,007
Current portion of finance lease liabilities	47,718	48,570
Current portion of operating lease liabilities	190,099	199,323
Current portion of grant repayable	54,168	55,855
Warrant liability	101,097	126,649
Total Current Liabilities	30,975,614	31,837,077
Long-term debt, net of current portion	3,865,357	3,624,860
Finance lease liabilities, net of current portion	363,927	400,022
Operating lease liabilities, net of current portion	350,810	378,054
Grant repayable, net of current portion	409,940	422,707
Total Long-Term Liabilities	4,990,034	4,825,643
Total Liabilities	35,965,648	36,662,720
Stockholders' Deficit
Common Stock Authorized: 100,000,000 shares of common stock, at $0.001 par value per share Issued and outstanding: 82,928,314 shares and 81,898,321 shares, respectively	82,928	81,898
Additional paid-in capital	195,755,863	194,448,414
Accumulated other comprehensive income	282,252	243,940
Accumulated deficit	(217,929,441)	(202,576,507)
Total VolitionRx Limited Stockholders' Deficit	(21,808,398)	(7,802,255)
Non-controlling interest	(1,089,213)	(909,967)
Total Stockholders' Deficit	(22,897,611)	(8,712,222)
Total Liabilities and Stockholders' Deficit	$ 13,068,037	$ 27,950,498

Condensed Consolidated Balanc_2

Condensed Consolidated Balance Sheets(Parenthetical) - $ / shares	Jun. 30, 2024	Dec. 31, 2023
Condensed Consolidated Balance Sheets
Common Stock, Shares Par Value	$ 0.001	$ 0.001
Common Stock, Shares Authorized	100,000,000	100,000,000
Common Stock, Shares Issued	82,928,314	81,898,321
Common Stock, Shares Outstanding	82,928,314	81,898,321

Condensed Consolidated Statemen

Condensed Consolidated Statements of Operations and Comprehensive Loss (Unaudited) - USD ($)	3 Months Ended		6 Months Ended
	Jun. 30, 2024	Jun. 30, 2023	Jun. 30, 2024	Jun. 30, 2023
Revenues
Services	$ 116,090	$ 50,163	$ 155,866	$ 55,519
Product	279,707	166,147	411,466	310,599
Total Revenues	395,797	216,310	567,332	366,118
Operating Expenses
Research and development	3,715,797	5,451,287	8,345,324	10,356,965
General and administrative	2,284,041	2,644,957	4,537,784	5,226,660
Sales and marketing	1,386,378	1,669,102	3,059,147	3,376,559
Total Operating Expenses	7,386,216	9,765,346	15,942,255	18,960,184
Operating Loss	(6,990,419)	(9,549,036)	(15,374,923)	(18,594,066)
Other Income (Expenses)
Grant income	0	0	0	165,795
Loss on disposal of fixed assets	(33,498)	0	(33,498)	0
Interest income	450	27,109	9,104	84,757
Interest expense	(81,182)	(58,321)	(158,415)	(109,643)
Gain on change in fair value of warrant liability	44,474	28,971	25,552	28,971
Total Other Income (Expenses)	(69,756)	(2,241)	(157,257)	169,880
Net Loss	(7,060,175)	(9,551,277)	(15,532,180)	(18,424,186)
Net Loss Attributable to Non-Controlling Interest	74,629	80,298	179,246	173,659
Net Loss Attributable to VolitionRx Limited Stockholders	(6,985,546)	(9,470,979)	(15,352,934)	(18,250,527)
Other Comprehensive Income (Loss)
Foreign currency translation adjustments	23,286	37,712	38,312	(18,766)
Net Comprehensive Loss	$ (7,036,889)	$ (9,513,565)	$ (15,493,868)	$ (18,442,952)
Net Loss Per Share - Basic and Diluted Attributable to VolitionRx Limited	$ (0.08)	$ (0.14)	$ (0.19)	$ (0.29)
Weighted Average Shares Outstanding - Basic and Diluted	82,669,335	66,884,368	82,312,161	63,613,224

Condensed Consolidated Statem_2

Condensed Consolidated Statements of Stockholders Equity (Unaudited) - USD ($)	Total	Common stock	Additional Paid-in Capital	Accumulated Other Comprehensive Income (Loss)	Accumulated Deficit	Noncontrolling Interest
Balance, shares at Dec. 31, 2022		57,873,379
Balance, amount at Dec. 31, 2022	$ (3,126,962)	$ 57,873	$ 164,397,468	$ 227,097	$ (167,257,429)	$ (551,971)
Common stock issued for cash, net of issuance costs, shares		5,225,703
Common stock issued for cash, net of issuance costs, amount	8,427,655	$ 5,225	8,422,430	0	0	0
Common stock issued for settlement of RSUs, shares		26,978
Common stock issued for settlement of RSUs, amount	0	$ 27	(27)	0	0	0
Stock-based compensation	693,657	0	693,657	0	0	0
Tax withholdings paid related to stock-based compensation	(14,336)	$ 0	(14,336)	0	0	0
Common stock repurchased, shares		(13,294)
Common stock repurchased, amount	(31,772)	$ (13)	(31,759)	0	0	0
Foreign currency translation	(56,478)	0	0	(56,478)	0	0
Net loss for the period	(8,872,909)	$ 0	0	0	(8,779,348)	(93,561)
Balance, shares at Mar. 31, 2023		63,112,766
Balance, amount at Mar. 31, 2023	(2,981,145)	$ 63,112	173,467,433	170,619	(176,036,777)	(645,532)
Balance, shares at Dec. 31, 2022		57,873,379
Balance, amount at Dec. 31, 2022	(3,126,962)	$ 57,873	164,397,468	227,097	(167,257,429)	(551,971)
Stock-based compensation	1,285,831
Net loss for the period	(18,424,186)
Balance, shares at Jun. 30, 2023		78,137,364
Balance, amount at Jun. 30, 2023	5,118,175	$ 78,137	191,065,293	208,331	(185,507,756)	(725,830)
Balance, shares at Mar. 31, 2023		63,112,766
Balance, amount at Mar. 31, 2023	(2,981,145)	$ 63,112	173,467,433	170,619	(176,036,777)	(645,532)
Common stock issued for cash, net of issuance costs, shares		14,950,000
Common stock issued for cash, net of issuance costs, amount	17,086,606	$ 14,950	17,071,656	0	0	0
Common stock issued for settlement of RSUs, shares		74,598
Common stock issued for settlement of RSUs, amount	0	$ 75	(75)	0	0	0
Stock-based compensation	592,174	0	592,174	0	0	0
Tax withholdings paid related to stock-based compensation	(65,895)	0	(65,895)	0	0	0
Foreign currency translation	37,712	0	0	37,712	0	0
Net loss for the period	(9,551,277)	$ 0	0	0	(9,470,979)	(80,298)
Balance, shares at Jun. 30, 2023		78,137,364
Balance, amount at Jun. 30, 2023	5,118,175	$ 78,137	191,065,293	208,331	(185,507,756)	(725,830)
Balance, shares at Dec. 31, 2023		81,898,321
Balance, amount at Dec. 31, 2023	(8,712,222)	$ 81,898	194,448,414	243,940	(202,576,507)	(909,967)
Common stock issued for cash, net of issuance costs, shares		13,350
Common stock issued for cash, net of issuance costs, amount	15,734	$ 13	15,721	0	0	0
Common stock issued for settlement of RSUs, shares		68,169
Common stock issued for settlement of RSUs, amount	0	$ 69	(69)	0	0	0
Stock-based compensation	411,220	0	411,220	0	0	0
Tax withholdings paid related to stock-based compensation	(3,062)	0	(3,062)	0	0	0
Foreign currency translation	15,026	0	0	15,026	0	0
Net loss for the period	(8,472,005)	$ 0	0	0	(8,367,388)	(104,617)
Common stock issued in lieu of license fee, shares		129,132
Common stock issued in lieu of license fee, amount	125,258	$ 129	125,129	0	0	0
Balance, shares at Mar. 31, 2024		82,108,972
Balance, amount at Mar. 31, 2024	(16,620,051)	$ 82,109	194,997,353	258,966	(210,943,895)	(1,014,584)
Balance, shares at Dec. 31, 2023		81,898,321
Balance, amount at Dec. 31, 2023	(8,712,222)	$ 81,898	194,448,414	243,940	(202,576,507)	(909,967)
Stock-based compensation	619,266
Net loss for the period	(15,532,180)
Balance, shares at Jun. 30, 2024		82,928,314
Balance, amount at Jun. 30, 2024	(22,897,611)	$ 82,928	195,755,863	282,252	(217,929,441)	(1,089,213)
Balance, shares at Mar. 31, 2024		82,108,972
Balance, amount at Mar. 31, 2024	(16,620,051)	$ 82,109	194,997,353	258,966	(210,943,895)	(1,014,584)
Common stock issued for cash, net of issuance costs, shares		734,155
Common stock issued for cash, net of issuance costs, amount	589,488	$ 734	588,754	0	0	0
Common stock issued for settlement of RSUs, shares		85,187
Common stock issued for settlement of RSUs, amount	0	$ 85	(85)	0	0	0
Stock-based compensation	208,046	0	208,046	0	0	0
Tax withholdings paid related to stock-based compensation	(38,205)	0	(38,205)	0	0	0
Foreign currency translation	23,286	0	0	23,286	0	0
Net loss for the period	(7,060,175)	$ 0	0	0	(6,985,546)	(74,629)
Balance, shares at Jun. 30, 2024		82,928,314
Balance, amount at Jun. 30, 2024	$ (22,897,611)	$ 82,928	$ 195,755,863	$ 282,252	$ (217,929,441)	$ (1,089,213)

Condensed Consolidated Statem_3

Condensed Consolidated Statements of Cash Flows (Unaudited) - USD ($)	6 Months Ended
	Jun. 30, 2024	Jun. 30, 2023
Operating Activities
Net loss	$ (15,532,180)	$ (18,424,186)
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation and amortization	532,504	560,313
Amortization of operating lease right-of-use assets	113,034	127,210
Loss on disposal of fixed assets	33,498	0
Stock-based compensation	619,266	1,285,831
Gain on change in fair value of warrant liability	(25,552)	(28,971)
Changes in operating assets and liabilities:
Prepaid expenses	(307,595)	(166,351)
Accounts receivable	76,357	(196,487)
Other current assets	9,198	(95,073)
Deferred revenue, current and non-current	(61,600)	0
Accounts payable and accrued liabilities	(384,567)	961,764
Management and directors' fees payable	(34,552)	9,019
Right-of-use assets operating leases liabilities	(112,199)	(125,393)
Net Cash Used In Operating Activities	(15,074,388)	(16,092,324)
Investing Activities
Purchases of property and equipment	(68,161)	(501,986)
Purchase of License	(171,095)	0
Net Cash Used In Investing Activities	(239,256)	(501,986)
Financing Activities
Net proceeds from issuances of common stock	605,222	25,881,221
Tax withholdings paid related to stock-based compensation	(41,267)	(80,231)
Common stock repurchased	0	(31,772)
Proceeds from long-term debt	754,457	216,908
Payments on long-term debt	(530,732)	(475,965)
Payments on finance lease obligations	(23,643)	(23,188)
Net Cash Provided By Financing Activities	764,037	25,486,973
Effect of foreign exchange on cash	(181,448)	(16,439)
Net change in cash and cash equivalents	(14,731,055)	8,876,224
Cash and cash equivalents - beginning of the period	20,729,983	10,867,050
Cash and cash equivalents - End of Period	5,998,928	19,743,274
Supplemental Disclosures of Cash Flow Information
Interest paid	158,415	109,643
Non-Cash Financing Activities
Common stock issued upon cashless exercises of stock options and settlement of vested RSUs	282	102
Offering costs from issuance of common stock	0	239,772
Fair value of warrants issued in connection with public offering	0	366,960
Common stock issued for License rights	125,258	0
Non-cash note payable	$ 294,603	$ 356,258

Basis of Presentation and Summa

Basis of Presentation and Summary of Significant Accounting Policies	6 Months Ended
	Jun. 30, 2024
Basis of Presentation and Summary of Significant Accounting Policies
Basis of Presentation and Summary of Significant Accounting Policies	Note 1 – Basis of Presentation and Summary of Significant Accounting Policies Basis of Presentation The accompanying unaudited condensed consolidated financial statements of VolitionRx Limited (the “Company” or “VolitionRx”) have been prepared in accordance with accounting principles generally accepted in the United States of America (“GAAP”) for interim financial information and with the instructions to Form 10-Q of Regulation S-X. They do not include all the information and footnotes required by GAAP for complete financial statements. The December 31, 2023 consolidated balance sheet data was derived from audited financial statements but do not include all disclosures required by GAAP. However, except as disclosed herein, there has been no material change in the information disclosed in the notes to the consolidated financial statements for the year ended December 31, 2023 included in the Company’s Annual Report on Form 10-K, as filed with the Securities and Exchange Commission on March 25, 2024 (the “Annual Report”). The interim unaudited condensed consolidated financial statements should be read in conjunction with those consolidated financial statements included in the Annual Report. In the opinion of management, all adjustments considered necessary for a fair presentation of the financial statements, consisting solely of normal recurring adjustments, have been made. Operating results for the six months ended June 30, 2024 are not necessarily indicative of the results that may be expected for the year ending December 31, 2024. Reclassifications Certain reclassifications within operating expenses have been made to the prior period’s financial statements to conform to the current period financial statement presentation. There is no impact in total to the results of operations and cash flows in all periods presented. Recently Issued Accounting Pronouncements In November 2023, the FASB issued ASU 2023-07, “ Segment Reporting (Topic 280): Improvements to Reportable Segment Disclosures In December 2023, the FASB issued ASU 2023-09, “ Income Taxes (Topic 740): Improvements to Income Tax Disclosures The Company currently believes there are no other issued and not yet effective accounting standards that are materially relevant to its condensed consolidated financial statements. Fair Value Measurements Pursuant to ASC 820, “ Fair Value Measurements and Disclosures,” Level 1 Level 1 applies to assets or liabilities for which there are quoted prices in active markets for identical assets or liabilities. Level 2 Level 2 applies to assets or liabilities for which there are inputs other than quoted prices that are observable for the assets or liabilities such as quoted prices for similar assets or liabilities in active markets; quoted prices for identical assets or liabilities in markets with insufficient volume or infrequent transactions (less active markets); or model-derived valuations in which significant inputs are observable or can be derived principally from, or corroborated by, observable market data. Level 3 Level 3 applies to assets or liabilities for which there are unobservable inputs to the valuation methodology that are significant to the measurement of the fair value of the assets or liabilities. The financial instruments of the Company consist primarily of cash and cash equivalents, accounts receivable, accounts payable, accrued liabilities, debt, and a warrant liability. These items are considered Level 1 due to their short-term nature and their market interest rates, except for the warrant liability, which is considered Level 2 and is recorded at fair value at the end of each reporting period. Included in the following table are the Company’s major categories of assets and liabilities measured at fair value on a recurring basis as of June 30, 2024. Fair Value Measurements at June 30, 2024 Description Level 1 Level 2 Level 3 Total $ $ $ $ Liabilities Warrant liability - 101,097 - 101,097 As of December 31, 2023, the warrant liability was $126,649. The following table provides a roll-forward of the warrant liability measured at fair value on a recurring basis for the six months ended June 30, 2024, as follows: Warrant Liability Total $ Balance at December 31, 2023 126,649 Gain on change in fair value of warrant liability (25,552 ) Balance at June 30, 2024 101,097 Basic and Diluted Net Loss Per Share The Company computes net loss per share in accordance with ASC 260, “ Earnings Per Share,”

Liquidity and Going Concern Ass

Liquidity and Going Concern Assessment	6 Months Ended
Liquidity and Going Concern Assessment	Jun. 30, 2024
Liquidity and Going Concern Assessment
Liquidity and Going Concern Assessment	Note 2 – Liquidity and Going Concern Assessment The Company's condensed consolidated financial statements are prepared using GAAP applicable to a going concern, which contemplates the realization of assets and liquidation of liabilities in the normal course of business. Management assesses liquidity and going concern uncertainty in the Company’s consolidated financial statements to determine whether there is sufficient cash on hand and working capital, including available borrowings on loans, to operate for a period of at least one year from the date the financial statements are issued, which is referred to as the “look-forward period,” as defined in GAAP. As part of this assessment, based on conditions that are known and reasonably knowable to management, management considered various scenarios, forecasts, projections, estimates and made certain key assumptions, including the timing and nature of projected cash expenditures or programs, its ability to delay or curtail expenditures or programs and its ability to raise additional capital, if necessary, among other factors. For the six months ended June 30, 2024, the Company incurred a net loss of $15.5 million and used cash flows in operating activities of $15.1 million. As of June 30, 2024, the Company had cash and cash equivalents of $6.0 million and an accumulated deficit of $217.9 million. The Company has generated operating losses and has experienced negative cash flows from operations since inception. The Company has not generated significant revenues and expects to incur further losses in the future, particularly from continued development of its clinical-stage diagnostic tests and commercialization activities. The future of the Company as an operating business will depend on its ability to obtain sufficient capital contributions, financing and/or generate revenues as may be required to sustain its operations. Management plans to address the above as needed by, (a) granting licenses and/or distribution rights to third parties in exchange for specified up-front and/or back-end payments, (b) obtaining additional financing through debt or equity transactions, (c) securing additional grant funds, and (d) developing and commercializing its products in an efficient manner. Management continues to exercise tight cost controls to conserve cash. As part of the Company’s cash conservation efforts, directors and certain employees have elected to exchange a portion of their salary for RSUs in the Company for a period of up to six months. The ability of the Company to continue as a going concern is dependent upon its ability to successfully accomplish the plans described in the preceding paragraph and to eventually attain profitable operations. Management assessed the mitigating effect of its plans to determine if it is probable that the plans would be effectively implemented within one year after the condensed consolidated financial statements are issued and when implemented, would mitigate the relevant conditions or events that raise substantial doubt about the Company’s ability to continue as a going concern. These plans are subject to market conditions and reliance on third parties, and there is no assurance that effective implementation of the Company’s plans will result in the necessary funding to continue current operations and satisfy current and expected debt obligations. The Company has implemented short-term cash preservation and cost-saving initiatives to conserve cash. The Company concluded that these plans do not alleviate the substantial doubt about the Company’s ability to continue as a going concern beyond one year from the date the condensed consolidated financial statements are issued. The accompanying condensed consolidated financial statements have been prepared assuming the Company will continue as a going concern, which contemplates the realization of assets and satisfaction of liabilities in the normal course of business. The accompanying consolidated financial statements do not include any adjustments relating to the recoverability and classification of assets and their carrying amounts, or the amounts and classification of liabilities that may result should the Company be unable to continue as a going concern. If the Company is unable to obtain adequate capital, it could be forced to cease operations.

Property and Equipment

Property and Equipment	6 Months Ended
Property and Equipment	Jun. 30, 2024
Property and Equipment
Property And Equipment	Note 3 - Property and Equipment The Company’s property and equipment consisted of the following amounts as of June 30, 2024 and December 31, 2023: June 30, 2024 December 31, 2023 Useful Life Cost $ Cost $ Computer hardware and software 3 years 723,206 724,534 Laboratory equipment 5 years 4,630,385 4,753,253 Office furniture and equipment 5 years 370,493 378,800 Buildings 30 years 2,049,211 2,113,031 Building improvements 5-15 years 1,574,428 1,610,016 Land Not amortized 128,467 132,468 Total property and equipment 9,476,190 9,712,102 Less accumulated depreciation 4,597,773 4,189,089 Total property and equipment net 4,878,417 5,523,013 During the six-month periods ended June 30, 2024 and June 30, 2023, the Company recognized $545,128 and $517,921, respectively, in depreciation expense.

Intangible Assets

Intangible Assets	6 Months Ended
Intangible Assets	Jun. 30, 2024
Intangible Assets
Intangible Assets	Note 4 - Intangible Assets The Company’s intangible assets consist of patents, mainly acquired in the acquisition of Belgian Volition. The patents are being amortized over the assets’ estimated useful lives, which range from 8 to 20 years. June 30, 2024 December 31, 2023 Cost $ Cost $ Patents 1,098,717 1,130,936 Licenses 296,353 - Total Patents and Licenses 1,395,070 1,130,936 Less accumulated amortization 1,062,849 1,107,050 Total patents and Licenses, net 332,221 23,886 During the six-month periods ended June 30, 2024 and June 30, 2023, the Company recognized $(12,624) and $42,392, respectively, in amortization expense. The Company amortizes the patents and licenses on a straight-line basis with terms ranging from 8 to 20 years. The annual estimated amortization schedule over the next five years is as follows: 2024 $ 16,057 2025 $ 20,448 2026 $ 20,448 2027 $ 20,448 2028 $ 20,448 Greater than 5 years $ 234,372 Total Intangible Assets $ 332,221 The Company periodically reviews its long-lived assets to ensure that their carrying value does not exceed their fair market value. The Company carried out such a review in accordance with ASC 360 “ Property, Plant and Equipment,

Related Party Transactions

Related Party Transactions	6 Months Ended
Related Party Transactions	Jun. 30, 2024
Related Party Transactions
Related-Party Transactions	No te 5 - Related-Party Transactions See Note 6, Common Stock Stock-Based Compensation,

Common Stock

Common Stock	6 Months Ended
Common Stock	Jun. 30, 2024
Common Stock
Common Stock	Note 6 - Common Stock As of June 30, 2024, the Company was authorized to issue 100 million shares of common stock, par value $0.001 per share, of which 82,928,314 and 81,898,321 shares were issued and outstanding as of June 30, 2024 and December 31, 2023, respectively. Stock Option Exercises During the six months ended June 30, 2024, no shares of common stock were issued pursuant to the exercise of stock options. Stock Options Expired / Cancelled On April 16, 2024, 36,821 vested stock options previously granted to an employee were cancelled and returned as authorized shares under the 2015 Plan on the expiration of the exercise period following the resignation of such employee. RSU Settlements Below is a table summarizing the RSUs vested and settled during the six months ended June 30, 2024, all of which were issued pursuant to the 2015 Plan. Equity Incentive Plan RSUs Vested (#) Vest Date Shares Issued (#) Shares Withheld for Taxes (#) 2015 21,582 Feb 8, 2024 21,582 - 2015 9,000 Mar 1, 2024 6,057 2,943 2015 44,217 Mar 27, 2024 40,530 3,687 2015 51,000 Apr 4, 2024 32,337 18,663 2015 50,000 May 1, 2024 34,496 15,504 2015 11,500 Jun 1, 2024 6,670 4,830 2015 14,962 Jun 15, 2024 11,684 3,278 202,261 153,356 48,905 Warrants Issued in Equity Capital Raise In connection with the June 2023 underwritten public offering of the Company’s common stock pursuant to the underwriting agreement with Prime Executions, Inc. dba Freedom Capital Markets (“Freedom”) dated June 1, 2023, the Company issued Freedom warrants to purchase an aggregate of 448,500 shares of Company common stock at an exercise price of $2.00 per share. The Company evaluated the warrants as either equity-classified or liability-classified instruments based on an assessment of the specific terms of the warrants and applicable authoritative guidance in ASC 480 and ASC 815-40. The Company determined the warrants issued to Freedom failed the indexation guidance under ASC 815-40, specifically, the warrants provide for a Black-Scholes value calculation in the event of certain transactions (“Fundamental Transactions”), which includes a floor on volatility utilized in the value calculation at 100% or greater. The Company has determined that this provision introduces leverage to the holders of the warrants that could result in a value that would be greater than the settlement amount of a fixed-for-fixed option on the Company’s own equity shares. Accordingly, pursuant to ASC 815-40, the Company has classified the fair value of the warrants as a liability upon issuance and marked to market each reporting period in the Company’s consolidated statement of operations until their exercise or expiration. Warrants Issued in Equity Capital Raise (continued) The fair value of the warrants as of June 30, 2024, and December 31, 2023, were $101,097 and $126,649 respectively. The warrant liability was estimated using the Black-Scholes pricing model with the following assumptions. June 30, 2024 December 31, 2023 Risk-free interest rate 4.43 % 3.89 % Expected volatility 82.80 % 76.30 % Expected life (years) 3.94 4.44 Expected dividend yield - - Total fair value $ 101,097 $ 126,649 The fair value of the warrants deemed to be a liability, due to certain contingent put features, was determined using the Black-Scholes option pricing model, which was deemed to be an appropriate model due to the terms of the warrants issued, including a fixed term and exercise price. Common Stock Issued for EpiCypher License Agreement On March 12, 2024, the Company issued 129,132 shares of restricted common stock to EpiCypher, Inc. at a price of $0.97 per share as partial consideration for license rights in connection with a License Agreement between EpiCypher and Belgian Volition. Equity Distribution Agreement On May 20, 2022, the Company entered into an equity distribution agreement (the “2022 EDA”) with Jefferies LLC (“Jefferies”) to sell shares of the Company’s common stock, with an aggregate offering price of up to $25.0 million, from time to time through an “at the market” offering pursuant to the Company’s Registration Statement on Form S-3 (File No. 333-259783) effective November 8, 2021) (the “2021 Form S-3”) through Jefferies acting as the Company’s agent and/or principal. The Company is not obligated to sell any shares under the 2022 EDA. During the six months ended June 30, 2024, the Company raised aggregate net proceeds (net of broker commissions and fees) of approximately $605,221 under the 2022 EDA through the sale of 747,505 shares of its common stock. As of June 30, 2024, the Company has raised aggregate net proceeds (net of broker commissions and fees) of approximately $2.1 million under the 2022 EDA through the sale of 1,378,037 shares of its common stock.

Stock Based Compensation

Stock Based Compensation	6 Months Ended
Stock Based Compensation	Jun. 30, 2024
Stock Based Compensation
Stock-based Compensation	Note 7 – Stock-Based Compensation a ) Warrants The following table summarizes the changes in warrants of the Company outstanding during the six-month period ended June 30, 2024. Number of Warrants Weighted Average Exercise Price ($) Outstanding at December 31, 2023 862,500 3.05 Granted - - Expired/Cancelled - - Outstanding at June 30, 2024 862,500 3.05 Exercisable at June 30, 2024 862,500 3.05 Below is a table summarizing the warrants issued and outstanding as of June 30, 2024, which have an aggregate weighted average remaining contractual life of 3.33 years. Number Outstanding Number Exercisable Exercise Price ($) Weighted Average Remaining Contractual Life (Years) Proceeds to Company if Exercised ($) 448,500 448,500 2.00 3.96 897,000 54,000 54,000 3.05 4.26 164,700 50,000 50,000 3.45 1.67 172,500 125,000 125,000 3.95 2.51 493,750 185,000 185,000 4.90 2.59 906,500 862,500 862,500 2,634,450 Stock-based compensation expense related to warrants of $5,238 and $20,320 was recorded in the six months ended June 30, 2024 and June 30, 2023, respectively. Total remaining unrecognized compensation cost related to non-vested warrants is $nil. As of June 30, 2024, the total intrinsic value of warrants outstanding was $nil. b) Options The following table summarizes the changes in options outstanding of the Company during the six-month period ended June 30, 2024. Number of Options Weighted Average Exercise Price ($) Outstanding at December 31, 2023 4,699,569 3.87 Expired/Cancelled (36,821 ) 3.40 Outstanding at June 30, 2024 4,662,748 3.88 Exercisable at June 30, 2024 4,662,748 3.88 b ) Options (continued) Below is a table summarizing the options issued and outstanding as of June 30, 2024, all of which were issued pursuant to the Company’s 2011 Equity Incentive Plan (for option issuances prior to 2016) or the 2015 Stock Incentive Plan (the “2015 Plan”) (for option and RSU issuances commencing in 2016)and which have an aggregate weighted average remaining contractual life of 3.71 years. As of June 30, 2024, an aggregate of 9,700,000 shares of common stock were authorized for issuance under the 2015 Plan, of which 354,782 shares of common stock remained available for future issuance thereunder. Number Outstanding Number Exercisable Exercise Price ($) Weighted Average Remaining Contractual Life (Years) Proceeds to Company if Exercised ($) 585,000 585,000 3.25 0.62 1,901,250 944,748 944,748 3.40 7.10 3,212,143 740,000 740,000 3.60 5.86 2,664,000 1,607,837 1,607,837 4.00 2.24 6,431,348 89,163 89,163 4.38 3.57 390,534 50,000 50,000 4.80 2.51 240,000 646,000 646,000 5.00 2.74 3,230,000 4,662,748 4,662,748 18,069,275 Stock-based compensation expense related to stock options of $nil and $235,368 was recorded in the six months ended June 30, 2024 and June 30, 2023, respectively. Total remaining unrecognized compensation cost related to non-vested stock options is $nil. As of June 30, 2024, the total intrinsic value of stock options outstanding was $nil. c ) Restricted Stock Units Below is a table summarizing the RSUs issued and outstanding as of June 30, 2024, all of which were issued pursuant to the 2015 Plan. RSUs (#) Weighted Average Grant Date Fair Value Share Price ($) Outstanding at December 31, 2023 3,634,952 1.01 Granted 426,340 0.72 Vested/Settled (202,261 ) 2.46 Cancelled / Forfeited (87,206 ) 1.13 Outstanding at June 30, 2024 3,771,825 0.89 c ) Restricted Stock Units (continued) Below is a table summarizing the RSUs granted during the six months ended June 30, 2024, all of which were issued pursuant to the 2015 Plan. The RSUs vest equally over periods stated on the dates noted, subject to the recipient’s continued service to the Company, and will result in the RSU compensation expense stated. On June 1, 2024, the Company granted 297,340 RSUs of common stock to certain directors and employees in exchange for their election to reduce their cash compensation for a period of three months for services provided to the Company. These RSUs will vest on May 1, 2025, subject to continued service by the recipient. Equity Incentive Plan RSUs Granted (#) Grant Date Vesting Period First Vesting Date Second Vesting Date Third Vesting Date RSU Expense ($) 2015 14,000 Feb 22, 2024 36 Months Feb 22, 2025 Feb 22, 2026 Feb 22, 2027 13,589 2015 115,000 May 23, 2024 36 Months May 23, 2025 May 23, 2026 May 23, 2027 85,389 2015 297,340 Jun 1, 2024 11 Months May 1, 2025 N/A N/A 209,832 426,340 308,810 Below is a table summarizing the RSUs vested and settled during the six months ended June 30, 2024, all of which were issued pursuant to the 2015 Plan. Equity Incentive Plan RSUs Vested (#) Vest Date Shares Issued (#) Shares Withheld for Taxes (#) 2015 21,582 Feb 8, 2024 21,582 - 2015 9,000 Mar 1, 2024 6,057 2,943 2015 44,217 Mar 27, 2024 40,530 3,687 2015 51,000 Apr 4, 2024 32,337 18,663 2015 50,000 May 1, 2024 34,496 15,504 2015 11,500 Jun 1, 2024 6,670 4,830 2015 14,962 Jun 15, 2024 11,684 3,278 202,261 153,356 48,905 c ) Restricted Stock Units (continued) Below is a table summarizing the RSUs cancelled during the six months ended June 30, 2024, all of which were originally issued pursuant to the 2015 Plan. Equity Incentive Plan RSUs (#) Cancellation Date Vesting Date RSUs Cancelled (#) 2015 8,000 Jan 16, 2024 Sep 28, 2024 8,000 2015 6,000 Jan 16, 2024 Oct 4, 2024 6,000 2015 8,000 Jan 16, 2024 Sep 28, 2025 8,000 2015 6,000 Jan 16, 2024 Oct 4, 2025 6,000 2015 8,000 Jan 16, 2024 Sep 28, 2026 8,000 2015 667 Feb 9, 2024 Jun 15, 2024 667 2015 667 Feb 9, 2024 Jun 15, 2025 667 2015 666 Feb 9, 2024 Jun 15, 2026 666 2015 1,775 Mar 25, 2024 Mar 27, 2024 1,775 2015 2,098 Mar 25, 2024 Jun 15, 2024 2,098 2015 2,667 May 17, 2024 Oct 4, 2024 2,667 2015 2,666 May 17, 2024 Oct 4, 2025 2,666 2015 1,000 May 17, 2024 Mar 27, 2025 1,000 2015 1,000 May 17, 2024 Mar 27, 2026 1,000 2015 3,334 May 17, 2024 Sep 28, 2024 3,334 2015 3,333 May 17, 2024 Sep 28, 2025 3,333 2015 3,333 May 17, 2024 Sep 28, 2026 3,333 2015 9,334 May 31, 2024 Sep 11, 2024 9,334 2015 9,333 May 31, 2024 Sep 11, 2025 9,333 2015 9,333 May 31, 2024 Sep 11, 2026 9,333 87,206 87,206 c ) Restricted Stock Units (continued) Below is a table summarizing the RSUs issued and outstanding as of June 30, 2024 and which have an aggregate weighted average remaining contractual life of 1.37 years. RSUs Outstanding (#) Weighted Average Grant Date Fair Value Share Price ($) Weighted Average Remaining Contractual Life (Years) 40,000 0.58 1.37 450,000 0.68 2.80 450,000 0.69 1.76 1,535,000 0.70 1.25 297,340 0.71 0.84 115,000 0.74 1.90 14,000 0.97 1.65 6,000 1.31 1.20 14,000 1.32 1.04 702,654 1.46 0.76 17,332 1.58 0.73 12,500 1.69 0.23 54,333 1.72 1.17 29,000 2.01 0.13 666 2.15 0.92 34,000 2.95 0.19 3,771,825 Stock-based compensation expense related to RSUs of $614,028 and $1,030,143 was recorded in the six months ended June 30, 2024 and June 30, 2023, respectively. Total remaining unrecognized compensation cost related to non-vested RSUs is $1,256,598.

Commitments and Contingencies

Commitments and Contingencies	6 Months Ended
Commitments and Contingencies	Jun. 30, 2024
Commitments and Contingencies
Commitments And Contingencies	Note 8 – Commitments and Contingencies a) Finance Lease Obligations The following is a schedule showing the future minimum lease payments under finance leases by years and the present value of the minimum payments as of June 30, 2024. 2024 - remaining $ 28,840 2025 $ 57,672 2026 $ 57,661 2027 $ 57,647 2028 $ 57,633 Greater than 5 years $ 194,395 Total $ 453,848 Less: Amount representing interest $ (42,203 ) Present value of minimum lease payments $ 411,645 b) Operating Lease Right-of-Use Obligations Operating leases as of June 30, 2024, and December 31, 2023, consisted of the following: June 30, 2024 December 31, 2023 $ $ Operating lease right-of-use assets 512,317 549,504 Operating lease liabilities, current portion 190,099 199,323 Operating lease liabilities, long term 350,810 378,054 Total operating lease liabilities 540,909 577,377 Weighted average remaining lease (months) 32 33 Weighted average discount rate 3.24 % 3.02 % During the six months ended June 30, 2024, cash paid for amounts included for the measurement of lease liabilities was $125,313 and the Company recorded operating lease expense of $126,217. b) Operating Lease Right-of-Use Obligations (continued) The following is a schedule showing the future minimum lease payments under operating leases by years and the present value of the minimum payments as of June 30, 2024. For the Six Months Ending June 30, 2024 Amount $ 2024 - Remaining 117,231 2025 191,273 2026 164,435 2027 92,151 2028 10,212 Total 575,302 Less: imputed interest (34,393 ) Total Operating Lease Liabilities 540,909 The Company’s office space leases are short-term and the Company has elected under the short-term recognition exemption not to recognize them on the balance sheet. During the six months ended June 30, 2024, the Company recognized $40,334 in short-term lease costs associated with office space leases. The annual payments remaining for short-term office leases were as follows: For the Six Months Ending June 30, 2024 Amount $ 2024 - Remaining 42,723 2025 7,198 Total Operating Lease Liabilities 49,921 c) Grants Repayable As of June 30, 2024, the total grant balance repayable was $464,108 and the payments remaining were as follows: For the Six Months Ending June 30, 2024 Amount $ 2024 - Remaining 54,169 2025 36,305 2026 43,756 2027 48,579 2028 51,951 Greater than 5 years 229,348 Total Grants Repayable 464,108 d) Long-Term Debt As of June 30, 2024, the total balance for long-term debt payable was $4,908,499 and the payments remaining were as follows: For the Six Months Ending June 30, 2024 Amount $ 2024 - Remaining 859,476 2025 1,005,297 2026 781,901 2027 583,641 2028 2,437,212 Greater than 5 years 314,022 Total 5,981,549 Less: amount representing interest (1,073,050 ) Total Long-Term Debt 4,908,499 e) Collaborative Agreement Obligations In 2018, the Company entered into a research collaboration agreement with the University of Taiwan for a three-year research period for a cost to the Company of up to $2.55 million payable over such period. As of June 30, 2024, $510,000 is still to be paid by the Company under this agreement. In 2022, the Company entered into a sponsored research agreement with The University of Texas MD Anderson Cancer Center to evaluate the role of neutrophil extracellular traps ("NETs") in cancer patients with sepsis for a cost to the Company of $449,406. As of June 30, 2024, $449,406 is still to be paid by the Company under this agreement. As of June 30, 2024, $204,087 is due by the Company under this agreement. In July 2023, the Company entered into a research agreement with Xenetic Biosciences Inc and CLS Therapeutics Ltd to evaluate the anti-tumoral effects of Nu.Q ® In August 2023, the Company entered into a project research agreement with Guy’s and St Thomas’ NHS Foundation Trust to evaluate the practical clinical utility of the Nu.Q ® In January 2024, the Company entered into an agreement with the University Medical Centre Amsterdam (“UMC”). UMC will perform a retrospective study to evaluate the diagnostic potential of the Nu.Q ® e) Collaborative Agreement Obligations (continued) As of June 30, 2024, the total amount to be paid for future research and collaboration commitments was $1,343,741 and the payments remaining were as follows: Total Amount Remaining 2024 - Estimated 2025 - Estimated $ $ $ National University of Taiwan 510,000 510,000 - MD Anderson Cancer Center 449,406 285,860 163,546 Guys and St Thomas 164,235 61,588 102,647 Xenetic Biosciences 81,447 26,142 55,305 UMC 138,653 92,343 46,310 Total Collaborative Obligations 1,343,741 975,933 367,808 f) Other Commitments Volition Germany As of June 30, 2024, $209 is payable under the royalty agreement with the founder of Volition’s former German subsidiary based on sales to date towards the Company’s aggregate minimum royalty obligation of $117,761. Volition America Effective February 10, 2024 the Company and Diagnostic Oncology CRO, LLC (“DXOCRO”) further amended and restated the August 2022 amended and restated Master Agreement by and between the Company and DXOCRO to expand the scope of DXOCRO’s consultant services provided thereunder (the “Second A&R Master Agreement”). The Second A&R Master Agreement requires DXOCRO to conduct a prospective optimization/range finding study of Volition’s Nu.Q ® VolitionRx On February 5, 2024, the Company entered into a 9-month loan agreement with First Insurance Funding for a maximum of $294,603 with fixed interest rate of 8.42%, maturing in November 2024. As of June 30, 2024, the maximum has been drawn down under this agreement and the principal balance payable was $163,668. The agreement is in relation to the directors and officers insurance policy. g) Legal Proceedings In the ordinary course of business, the Company may be subject to claims, counter-claims, lawsuits and other litigation of the type that generally arise from the conduct of its business. The Company knows of no legal proceedings which the Company believes will have a material adverse effect on its financial position. h) Commitments in Respect of Corporate Goals and Performance-Based Awards As of June 30, 2024, the Company has recognized total compensation expense of $1,291,594 of which $527,940 is in relation to RSUs from grants in 2022 that vested in 2023, $451,490 is in relation to RSUs from such grants that will vest in 2024, and $312,164 is in relation to RSUs from such grants that will vest in 2025. The Company has unrecognized compensation expense of $282,823 in relation to such RSUs, based on the outcomes related to the prescribed performance targets on the outstanding awards. Total Vesting Amortized Amortized Amortized Un-Amortized Award Year 2024 2023 2022 $ $ $ $ $ 527,940 2023 - 393,853 134,087 - 517,613 2024 126,283 260,119 65,088 66,123 528,864 2025 87,894 177,584 46,686 216,700 1,574,417 214,177 831,556 245,861 282,823 In September 2023, the Compensation Committee of the Board of Directors approved the granting of cash bonuses, payable upon achievement of various corporate goals focused around revenue, operations and regulatory, to various personnel including directors, executives, members of management, consultants and employees of the Company and/or its subsidiaries. Pursuant to the terms of the grants, conditional upon the achievement by December 31, 2023 and June 30, 2024 of specified corporate goals as set forth in the minutes of the Compensation Committee, as well as continued service by the award recipients to the Company, the Company at the sole discretion of the Chief Executive Officer and the Chief Financial Officer would pay a cash bonus to such award recipients. As of June 30, 2024, the Company has accrued compensation expense of $536,535 in relation to cash bonuses payable on the achievement of specified corporate goals based on the expected outcomes related to the prescribed performance targets. To the extent this is payable, this cash bonus compensation payment has currently been deferred indefinitely. As of June 30, 2024, the Company had recognized total compensation expense of $335,013. The Company has unrecognized compensation expense of $390,276 in relation to the RSUs from grants in 2023, of which $59,290 is in relation to RSUs that will vest in 2024, $150,277 in relation to RSUs that will vest in 2025, and $180,709 in relation to RSUs that will vest in 2026 based on the outcomes related to the prescribed performance targets on the outstanding awards. Total Vesting Amortized Amortized Un-Amortized Award Year 2024 2023 2024 $ $ $ $ 241,771 2024 118,511 63,970 59,290 241,764 2025 59,416 32,071 150,277 241,754 2026 39,645 21,400 180,709 725,289 217,572 117,441 390,276

Subsequent Events

Subsequent Events	6 Months Ended
Subsequent Events	Jun. 30, 2024
Subsequent Events
Subsequent Events	Note 9 – Subsequent Events Settlement of RSUs On July 13, 2024, 4,667 RSUs previously granted to various employees vested and resulted in the issuance of 3,165 shares of common stock. 1,502 shares of common stock were withheld for taxes and returned to the 2015 Plan. RSUs Granted Effective July 1, 2024, the Company granted RSUs of 38,198 shares of common stock to an employee of the Company in exchange their valid election to reduce their cash compensation for a period of three months for services provided to the Company. These RSUs will vest on June 1, 2025, subject to continued service by the employee. Effective July 8, 2024, the Company granted RSUs of 21,583 shares of common stock to an advisor of the Company and/or its subsidiaries in exchange for services provided to the Company and/or its subsidiaries. These RSUs vest upon the achievement of advisory services set out in the agreement with 21,583 vesting on January 1, 2025, subject to continued service, and will result in total compensation expense of $13,209. RSUs Cancelled On July 12, 2024, 19,666 RSUs previously granted to an employee were cancelled and returned as authorized and unissued shares under the 2015 Plan upon termination of employment prior to vesting. On August 4, 2024, 46,333 RSUs previously granted to an employee were cancelled and returned as authorized and unissued shares under the 2015 Plan upon termination of employment prior to vesting. Increase in Authorised Capital At the Annual Meeting on July 2, 2024, the Company’s stockholders approved a Certificate of Amendment of the Second Amended and Restated Certificate of Incorporation providing for an increase in authorized shares from one hundred million (100,000,000) to one hundred seventy-five million (175,000,000) shares, consisting of one hundred seventy-five million (175,000,000) shares of common stock, par value $0.001 per share. Equity Capital Raise On August 8, 2024, the Company entered into a securities purchase agreement with a purchaser pursuant to which the Company issued and sold to such purchaser, in a registered direct offering under the 2021 Form S-3, an aggregate of 9,170,000 shares of the Company’s common stock, pre-funded warrants to purchase up to 3,557,273 shares of the Company’s common stock (the “Pre-Funded Warrants”), Series A common stock warrants to purchase up to 12,727,273 shares of the Company’s common stock (the “Series A Warrants”) and Series B common stock warrants to purchase up to 12,727,273 shares of the Company’s common stock (the “Series B Warrants” and, together with the Series A Warrants, the “Common Warrants”). The exercise prices of the Pre-Funded Warrants and the Common Warrants are $0.001 per share and $0.57 per share, respectively. H.C. Wainwright & Co. acted as the exclusive placement agent for the Company in the offering. The combined offering price for a share of common stock and accompanying Common Warrants was $0.55 and the combined offering price for a Pre-Funded Warrant and accompanying Common Warrants was $0.549. The net proceeds received by the Company for the issuance and sale of the shares of Common Stock, the Pre-Funded Warrants and the Common Warrants (collectively, the “Securities”) was $6.4 million, before deducting offering expenses of $0.1 million paid by the Company. In addition, the Company issued warrants to purchase an aggregate of 381,818 shares of Company common stock to the placement agent, on substantially the same terms as the Series B Warrants at an exercise price of $0.6875 per share. The net proceeds above assumes the exercise of the Pre-Funded Warrants but excludes any proceeds arising from the exercise of the Common Warrants or the Placement Agent Warrants.

Basis of Presentation and Sum_2

Basis of Presentation and Summary of Significant Accounting Policies (Policies)	6 Months Ended
	Jun. 30, 2024
Basis of Presentation and Summary of Significant Accounting Policies
Basis Of Presentation	The accompanying unaudited condensed consolidated financial statements of VolitionRx Limited (the “Company” or “VolitionRx”) have been prepared in accordance with accounting principles generally accepted in the United States of America (“GAAP”) for interim financial information and with the instructions to Form 10-Q of Regulation S-X. They do not include all the information and footnotes required by GAAP for complete financial statements. The December 31, 2023 consolidated balance sheet data was derived from audited financial statements but do not include all disclosures required by GAAP. However, except as disclosed herein, there has been no material change in the information disclosed in the notes to the consolidated financial statements for the year ended December 31, 2023 included in the Company’s Annual Report on Form 10-K, as filed with the Securities and Exchange Commission on March 25, 2024 (the “Annual Report”). The interim unaudited condensed consolidated financial statements should be read in conjunction with those consolidated financial statements included in the Annual Report. In the opinion of management, all adjustments considered necessary for a fair presentation of the financial statements, consisting solely of normal recurring adjustments, have been made. Operating results for the six months ended June 30, 2024 are not necessarily indicative of the results that may be expected for the year ending December 31, 2024.
Reclassification	Certain reclassifications within operating expenses have been made to the prior period’s financial statements to conform to the current period financial statement presentation. There is no impact in total to the results of operations and cash flows in all periods presented.
Recently Issued Accounting Pronouncements	In November 2023, the FASB issued ASU 2023-07, “ Segment Reporting (Topic 280): Improvements to Reportable Segment Disclosures In December 2023, the FASB issued ASU 2023-09, “ Income Taxes (Topic 740): Improvements to Income Tax Disclosures The Company currently believes there are no other issued and not yet effective accounting standards that are materially relevant to its condensed consolidated financial statements.
Fair Value Measurements	Pursuant to ASC 820, “ Fair Value Measurements and Disclosures,” Level 1 Level 1 applies to assets or liabilities for which there are quoted prices in active markets for identical assets or liabilities. Level 2 Level 2 applies to assets or liabilities for which there are inputs other than quoted prices that are observable for the assets or liabilities such as quoted prices for similar assets or liabilities in active markets; quoted prices for identical assets or liabilities in markets with insufficient volume or infrequent transactions (less active markets); or model-derived valuations in which significant inputs are observable or can be derived principally from, or corroborated by, observable market data. Level 3 Level 3 applies to assets or liabilities for which there are unobservable inputs to the valuation methodology that are significant to the measurement of the fair value of the assets or liabilities. The financial instruments of the Company consist primarily of cash and cash equivalents, accounts receivable, accounts payable, accrued liabilities, debt, and a warrant liability. These items are considered Level 1 due to their short-term nature and their market interest rates, except for the warrant liability, which is considered Level 2 and is recorded at fair value at the end of each reporting period. Included in the following table are the Company’s major categories of assets and liabilities measured at fair value on a recurring basis as of June 30, 2024. Fair Value Measurements at June 30, 2024 Description Level 1 Level 2 Level 3 Total $ $ $ $ Liabilities Warrant liability - 101,097 - 101,097 As of December 31, 2023, the warrant liability was $126,649. The following table provides a roll-forward of the warrant liability measured at fair value on a recurring basis for the six months ended June 30, 2024, as follows: Warrant Liability Total $ Balance at December 31, 2023 126,649 Gain on change in fair value of warrant liability (25,552 ) Balance at June 30, 2024 101,097
Basic And Diluted Net Loss Per Share	The Company computes net loss per share in accordance with ASC 260, “ Earnings Per Share,”

Basis of Presentation and Sum_3

Basis of Presentation and Summary of Significant Accounting Policies (Tables)	6 Months Ended
	Jun. 30, 2024
Basis of Presentation and Summary of Significant Accounting Policies
Schedule Of assets and liabilities measured at fair value on a recurring basis	Fair Value Measurements at June 30, 2024 Description Level 1 Level 2 Level 3 Total $ $ $ $ Liabilities Warrant liability - 101,097 - 101,097
Schedule Of warrant liability measured at fair value	Warrant Liability Total $ Balance at December 31, 2023 126,649 Gain on change in fair value of warrant liability (25,552 ) Balance at June 30, 2024 101,097

Property and Equipment (Tables)

Property and Equipment (Tables)	6 Months Ended
Property and Equipment (Tables)	Jun. 30, 2024
Property and Equipment
Schedule Of Property And Equipment	June 30, 2024 December 31, 2023 Useful Life Cost $ Cost $ Computer hardware and software 3 years 723,206 724,534 Laboratory equipment 5 years 4,630,385 4,753,253 Office furniture and equipment 5 years 370,493 378,800 Buildings 30 years 2,049,211 2,113,031 Building improvements 5-15 years 1,574,428 1,610,016 Land Not amortized 128,467 132,468 Total property and equipment 9,476,190 9,712,102 Less accumulated depreciation 4,597,773 4,189,089 Total property and equipment net 4,878,417 5,523,013

Intangible Assets (Tables)

Intangible Assets (Tables)	6 Months Ended
Intangible Assets (Tables)	Jun. 30, 2024
Intangible Assets
Schedule Of Intangible Assets	June 30, 2024 December 31, 2023 Cost $ Cost $ Patents 1,098,717 1,130,936 Licenses 296,353 - Total Patents and Licenses 1,395,070 1,130,936 Less accumulated amortization 1,062,849 1,107,050 Total patents and Licenses, net 332,221 23,886
Schedule Of Annual Estimated Amortization	2024 $ 16,057 2025 $ 20,448 2026 $ 20,448 2027 $ 20,448 2028 $ 20,448 Greater than 5 years $ 234,372 Total Intangible Assets $ 332,221

Common Stock (Tables)

Common Stock (Tables)	6 Months Ended
Common Stock (Tables)	Jun. 30, 2024
Common Stock
Summary of RSUs vested and settled during period	Equity Incentive Plan RSUs Vested (#) Vest Date Shares Issued (#) Shares Withheld for Taxes (#) 2015 21,582 Feb 8, 2024 21,582 - 2015 9,000 Mar 1, 2024 6,057 2,943 2015 44,217 Mar 27, 2024 40,530 3,687 2015 51,000 Apr 4, 2024 32,337 18,663 2015 50,000 May 1, 2024 34,496 15,504 2015 11,500 Jun 1, 2024 6,670 4,830 2015 14,962 Jun 15, 2024 11,684 3,278 202,261 153,356 48,905
Schedule of fair value of the warrants	June 30, 2024 December 31, 2023 Risk-free interest rate 4.43 % 3.89 % Expected volatility 82.80 % 76.30 % Expected life (years) 3.94 4.44 Expected dividend yield - - Total fair value $ 101,097 $ 126,649

Stock Based Compensation (Table

Stock Based Compensation (Tables)	6 Months Ended
Stock Based Compensation (Tables)	Jun. 30, 2024
Stock Based Compensation
Summary Of Changes In Warrants Outstanding	Number of Warrants Weighted Average Exercise Price ($) Outstanding at December 31, 2023 862,500 3.05 Granted - - Expired/Cancelled - - Outstanding at June 30, 2024 862,500 3.05 Exercisable at June 30, 2024 862,500 3.05
Summarizing The Warrants Issued And Outstanding	Number Outstanding Number Exercisable Exercise Price ($) Weighted Average Remaining Contractual Life (Years) Proceeds to Company if Exercised ($) 448,500 448,500 2.00 3.96 897,000 54,000 54,000 3.05 4.26 164,700 50,000 50,000 3.45 1.67 172,500 125,000 125,000 3.95 2.51 493,750 185,000 185,000 4.90 2.59 906,500 862,500 862,500 2,634,450
Summarizes The Changes In Options Outstanding	Number of Options Weighted Average Exercise Price ($) Outstanding at December 31, 2023 4,699,569 3.87 Expired/Cancelled (36,821 ) 3.40 Outstanding at June 30, 2024 4,662,748 3.88 Exercisable at June 30, 2024 4,662,748 3.88
Summarizing The Options Issued And Outstanding	Number Outstanding Number Exercisable Exercise Price ($) Weighted Average Remaining Contractual Life (Years) Proceeds to Company if Exercised ($) 585,000 585,000 3.25 0.62 1,901,250 944,748 944,748 3.40 7.10 3,212,143 740,000 740,000 3.60 5.86 2,664,000 1,607,837 1,607,837 4.00 2.24 6,431,348 89,163 89,163 4.38 3.57 390,534 50,000 50,000 4.80 2.51 240,000 646,000 646,000 5.00 2.74 3,230,000 4,662,748 4,662,748 18,069,275
Summarizing The Rsus Issued And Outstanding	RSUs (#) Weighted Average Grant Date Fair Value Share Price ($) Outstanding at December 31, 2023 3,634,952 1.01 Granted 426,340 0.72 Vested/Settled (202,261 ) 2.46 Cancelled / Forfeited (87,206 ) 1.13 Outstanding at June 30, 2024 3,771,825 0.89
Schedule of RSUs granted during period	Equity Incentive Plan RSUs Granted (#) Grant Date Vesting Period First Vesting Date Second Vesting Date Third Vesting Date RSU Expense ($) 2015 14,000 Feb 22, 2024 36 Months Feb 22, 2025 Feb 22, 2026 Feb 22, 2027 13,589 2015 115,000 May 23, 2024 36 Months May 23, 2025 May 23, 2026 May 23, 2027 85,389 2015 297,340 Jun 1, 2024 11 Months May 1, 2025 N/A N/A 209,832 426,340 308,810
Schedule of RSUs vested and settled during period	Equity Incentive Plan RSUs Vested (#) Vest Date Shares Issued (#) Shares Withheld for Taxes (#) 2015 21,582 Feb 8, 2024 21,582 - 2015 9,000 Mar 1, 2024 6,057 2,943 2015 44,217 Mar 27, 2024 40,530 3,687 2015 51,000 Apr 4, 2024 32,337 18,663 2015 50,000 May 1, 2024 34,496 15,504 2015 11,500 Jun 1, 2024 6,670 4,830 2015 14,962 Jun 15, 2024 11,684 3,278 202,261 153,356 48,905
Schedule of RSUs cancelled	Equity Incentive Plan RSUs (#) Cancellation Date Vesting Date RSUs Cancelled (#) 2015 8,000 Jan 16, 2024 Sep 28, 2024 8,000 2015 6,000 Jan 16, 2024 Oct 4, 2024 6,000 2015 8,000 Jan 16, 2024 Sep 28, 2025 8,000 2015 6,000 Jan 16, 2024 Oct 4, 2025 6,000 2015 8,000 Jan 16, 2024 Sep 28, 2026 8,000 2015 667 Feb 9, 2024 Jun 15, 2024 667 2015 667 Feb 9, 2024 Jun 15, 2025 667 2015 666 Feb 9, 2024 Jun 15, 2026 666 2015 1,775 Mar 25, 2024 Mar 27, 2024 1,775 2015 2,098 Mar 25, 2024 Jun 15, 2024 2,098 2015 2,667 May 17, 2024 Oct 4, 2024 2,667 2015 2,666 May 17, 2024 Oct 4, 2025 2,666 2015 1,000 May 17, 2024 Mar 27, 2025 1,000 2015 1,000 May 17, 2024 Mar 27, 2026 1,000 2015 3,334 May 17, 2024 Sep 28, 2024 3,334 2015 3,333 May 17, 2024 Sep 28, 2025 3,333 2015 3,333 May 17, 2024 Sep 28, 2026 3,333 2015 9,334 May 31, 2024 Sep 11, 2024 9,334 2015 9,333 May 31, 2024 Sep 11, 2025 9,333 2015 9,333 May 31, 2024 Sep 11, 2026 9,333 87,206 87,206
Schedule of RSUs issued and outstanding and average contractual life	RSUs Outstanding (#) Weighted Average Grant Date Fair Value Share Price ($) Weighted Average Remaining Contractual Life (Years) 40,000 0.58 1.37 450,000 0.68 2.80 450,000 0.69 1.76 1,535,000 0.70 1.25 297,340 0.71 0.84 115,000 0.74 1.90 14,000 0.97 1.65 6,000 1.31 1.20 14,000 1.32 1.04 702,654 1.46 0.76 17,332 1.58 0.73 12,500 1.69 0.23 54,333 1.72 1.17 29,000 2.01 0.13 666 2.15 0.92 34,000 2.95 0.19 3,771,825

Commitments and Contingencies (

Commitments and Contingencies (Tables)	6 Months Ended
Commitments and Contingencies (Tables)	Jun. 30, 2024
Commitments and Contingencies
Schedule of future minimum lease payments under financing leases	2024 - remaining $ 28,840 2025 $ 57,672 2026 $ 57,661 2027 $ 57,647 2028 $ 57,633 Greater than 5 years $ 194,395 Total $ 453,848 Less: Amount representing interest $ (42,203 ) Present value of minimum lease payments $ 411,645
Schedule of operating lease	June 30, 2024 December 31, 2023 $ $ Operating lease right-of-use assets 512,317 549,504 Operating lease liabilities, current portion 190,099 199,323 Operating lease liabilities, long term 350,810 378,054 Total operating lease liabilities 540,909 577,377 Weighted average remaining lease (months) 32 33 Weighted average discount rate 3.24 % 3.02 %
Schedule Of Future Minimum Lease Payments Under Operating Leases	For the Six Months Ending June 30, 2024 Amount $ 2024 - Remaining 117,231 2025 191,273 2026 164,435 2027 92,151 2028 10,212 Total 575,302 Less: imputed interest (34,393 ) Total Operating Lease Liabilities 540,909
Schedule Of Recognized In Short-term Lease Costs	For the Six Months Ending June 30, 2024 Amount $ 2024 - Remaining 42,723 2025 7,198 Total Operating Lease Liabilities 49,921
Schedule Of Grants Repayable	For the Six Months Ending June 30, 2024 Amount $ 2024 - Remaining 54,169 2025 36,305 2026 43,756 2027 48,579 2028 51,951 Greater than 5 years 229,348 Total Grants Repayable 464,108
Schedule Of Long-term Debt Payable	For the Six Months Ending June 30, 2024 Amount $ 2024 - Remaining 859,476 2025 1,005,297 2026 781,901 2027 583,641 2028 2,437,212 Greater than 5 years 314,022 Total 5,981,549 Less: amount representing interest (1,073,050 ) Total Long-Term Debt 4,908,499
Schedule of annual payments Of Collaborative Agreement Obligations	Total Amount Remaining 2024 - Estimated 2025 - Estimated $ $ $ National University of Taiwan 510,000 510,000 - MD Anderson Cancer Center 449,406 285,860 163,546 Guys and St Thomas 164,235 61,588 102,647 Xenetic Biosciences 81,447 26,142 55,305 UMC 138,653 92,343 46,310 Total Collaborative Obligations 1,343,741 975,933 367,808
Schedule of commitments in respect of corporate goals and performance based awards	Total Vesting Amortized Amortized Amortized Un-Amortized Award Year 2024 2023 2022 $ $ $ $ $ 527,940 2023 - 393,853 134,087 - 517,613 2024 126,283 260,119 65,088 66,123 528,864 2025 87,894 177,584 46,686 216,700 1,574,417 214,177 831,556 245,861 282,823 Total Vesting Amortized Amortized Un-Amortized Award Year 2024 2023 2024 $ $ $ $ 241,771 2024 118,511 63,970 59,290 241,764 2025 59,416 32,071 150,277 241,754 2026 39,645 21,400 180,709 725,289 217,572 117,441 390,276

Basis of Presentation and Sum_4

Basis of Presentation and Summary of Significant Accounting Policies (Details) - USD ($)	Jun. 30, 2024	Dec. 31, 2023
Warrant liability	$ 101,097	$ 126,649
Fair Value Inputs Level 1 [Member]
Warrant liability	0
Fair Value Inputs Level 2 [Member]
Warrant liability	101,097
Fair Value Inputs Level 3 [Member]
Warrant liability	$ 0

Basis of Presentation and Sum_5

Basis of Presentation and Summary of Significant Accounting Policies (Details 1)	6 Months Ended
	Jun. 30, 2024 USD ($)
Basis of Presentation and Summary of Significant Accounting Policies
Warrant Liability beginning balance	$ 126,649
Gain on change in fair value of warrant liability	(25,552)
Warrant Liability ending balance	$ 101,097

Basis of Presentation and Sum_6

Basis of Presentation and Summary of Significant Accounting Policies (Details Narrative) - USD ($)	6 Months Ended
	Jun. 30, 2024	Dec. 31, 2023
Basis of Presentation and Summary of Significant Accounting Policies
Warrant Liability	$ 101,097	$ 126,649
Potentially Dilutive Securities Excluded From The Computation Of Eps	9,297,073

Liquidity and Going Concern A_2

Liquidity and Going Concern Assessment (Details Narrative) - USD ($)	3 Months Ended				6 Months Ended
	Jun. 30, 2024	Mar. 31, 2024	Jun. 30, 2023	Mar. 31, 2023	Jun. 30, 2024	Jun. 30, 2023	Dec. 31, 2023
Accumulated deficit	$ (217,929,441)				$ (217,929,441)		$ (202,576,507)
Cash flows from operating activities					(15,074,388)	$ (16,092,324)
Net Loss	(7,060,175)	$ (8,472,005)	$ (9,551,277)	$ (8,872,909)	(15,532,180)	$ (18,424,186)
Liquidity and Going Concern Assessment [Member]
Accumulated deficit	(217,900,000)				(217,900,000)
Cash and cash equivalents	$ 6,000,000				6,000,000
Cash flows from operating activities					15,100,000
Net Loss					$ (15,500,000)

Property and Equipment (Details

Property and Equipment (Details) - USD ($)	6 Months Ended
Property and Equipment (Details) - USD ($)	Jun. 30, 2024	Dec. 31, 2023
Total property and equipment	$ 9,476,190	$ 9,712,102
Less accumulated depreciation	4,597,773	4,189,089
Total property and equipment net	4,878,417	5,523,013
Computer Hardware And Software [Member]
Total property and equipment	$ 723,206	724,534
Estimated useful life	3 years
Laboratory Equipment [Member]
Total property and equipment	$ 4,630,385	4,753,253
Estimated useful life	5 years
Office Furniture and Equipment [Member]
Total property and equipment	$ 370,493	378,800
Estimated useful life	5 years
Buildings [Member]
Total property and equipment	$ 2,049,211	2,113,031
Estimated useful life	30 years
Building Improvements [Member]
Total property and equipment	$ 1,574,428	1,610,016
Building Improvements [Member] \| Minimum [Member]
Estimated useful life	5 years
Building Improvements [Member] \| Maximum [Member]
Estimated useful life	15 years
Land [Member]
Total property and equipment	$ 128,467	$ 132,468

Property and Equipment (Detai_2

Property and Equipment (Details Narrative) - USD ($)	6 Months Ended
Property and Equipment (Details Narrative) - USD ($)	Jun. 30, 2024	Jun. 30, 2023
Property and Equipment
Depreciation Expense	$ 545,128	$ 517,921

Intangible Assets (Details)

Intangible Assets (Details) - USD ($)	Jun. 30, 2024	Dec. 31, 2023
Total Patents and Licenses	$ 1,395,070	$ 1,130,936
Less accumulated amortization	1,062,849	1,107,050
Total patents and Licenses, net	332,221	23,886
Patents [Member]
Total Patents and Licenses	1,098,717	1,130,936
Licenses [Member]
Total Patents and Licenses	$ 296,353	$ 0

Intangible Assets (Details 1)

Intangible Assets (Details 1) - USD ($)	Jun. 30, 2024	Dec. 31, 2023
Intangible Assets
2024	$ 16,057
2025	20,448
2026	20,448
2027	20,448
2028	20,448
Greater than 5 years	234,372
Total Intangible Assets	$ 332,221	$ 23,886

Intangible Assets (Details Narr

Intangible Assets (Details Narrative) - USD ($)	6 Months Ended
Intangible Assets (Details Narrative) - USD ($)	Jun. 30, 2024	Jun. 30, 2023
Amortization Expense	$ (12,624)	$ 42,392
Minimum [Member] \| Patents And Intellectual Property [Member]
Amortization Of Patents On Straight Line Basis	8 years
Maximum [Member] \| Patents And Intellectual Property [Member]
Amortization Of Patents On Straight Line Basis	20 years

Common Stock (Details)

Common Stock (Details)	6 Months Ended
Common Stock (Details)	Jun. 30, 2024 USD ($) shares
Equity Incentive RSU	202,261
Incentive RSU Issued	153,356
RSUs Held for Taxes \| $	$ 48,905
Equity Incentive Plan One [Member]
Incentive Plan	2015
Equity Incentive RSU	21,582
Incentive Vest Date	Feb. 08, 2024
Incentive RSU Issued	21,582
RSUs Held for Taxes \| $	$ 0
Equity Incentive Plan Two [Member]
Incentive Plan	2015
Equity Incentive RSU	9,000
Incentive Vest Date	Mar. 01, 2024
Incentive RSU Issued	6,057
RSUs Held for Taxes \| $	$ 2,943
Equity Incentive Plan Three [Member]
Incentive Plan	2015
Equity Incentive RSU	44,217
Incentive Vest Date	Mar. 27, 2024
Incentive RSU Issued	40,530
RSUs Held for Taxes \| $	$ 3,687
Equity Incentive Plan Four [Member]
Incentive Plan	2015
Equity Incentive RSU	51,000
Incentive Vest Date	Apr. 04, 2024
Incentive RSU Issued	32,337
RSUs Held for Taxes \| $	$ 18,663
Equity Incentive Plan Five [Member]
Incentive Plan	2015
Equity Incentive RSU	50,000
Incentive Vest Date	May 01, 2024
Incentive RSU Issued	34,496
RSUs Held for Taxes \| $	$ 15,504
Equity Incentive Plan Six [Member]
Incentive Plan	2015
Equity Incentive RSU	11,500
Incentive Vest Date	Jun. 01, 2024
Incentive RSU Issued	6,670
RSUs Held for Taxes \| $	$ 4,830
Equity Incentive Plan Seven [Member]
Incentive Plan	2015
Equity Incentive RSU	14,962
Incentive Vest Date	Jun. 15, 2024
Incentive RSU Issued	11,684
RSUs Held for Taxes \| $	$ 3,278

Common Stock (Details 1)

Common Stock (Details 1) - USD ($)	6 Months Ended	12 Months Ended
Common Stock (Details 1) - USD ($)	Jun. 30, 2024	Dec. 31, 2023
Common Stock
Risk-free interest rate	4.43%	3.89%
Expected volatility	82.80%	76.30%
Expected term (years)	3 years 11 months 8 days	4 years 5 months 8 days
Expected dividend yield	0%	0%
Total fair value	$ 101,097	$ 126,649

Common Stock (Details Narrative

Common Stock (Details Narrative) - USD ($)		1 Months Ended			6 Months Ended	12 Months Ended
Common Stock (Details Narrative) - USD ($)	Mar. 12, 2024	Apr. 16, 2024	Jun. 30, 2023	May 20, 2022	Jun. 30, 2024	Dec. 31, 2023
Common stock price per share					$ 0.001
Common stock, shares authorized					100,000,000
Common stock, shares issued					82,928,314	81,898,321
Common stock, shares outstanding					82,928,314	81,898,321
Total fair value					$ 101,097	$ 126,649
2015 [Member]
Vested stock options		36,821
Underwriting Agreement [Member]
Total fair value					$ 101,097	$ 126,649
Warrants issued to purchase shares of common stock			448,500
Exercise price			$ 2
EpiCypher License Agreement [Member]
Common stock price per share	$ 0.97
Issuance of restricted common stock	129,132
Equity Distribution Agreement [Member]
Common stock shares sold					747,505
Aggeregate share of common stock offering price				$ 25,000,000
Aggregate net proceeds					$ 605,221
2022 EDA [Member]
Common stock shares sold					1,378,037
Commissions and fee					$ 2,100,000

StockBased Compensation (Detail

StockBased Compensation (Details) - Warrants [Member]	6 Months Ended
StockBased Compensation (Details) - Warrants [Member]	Jun. 30, 2024 $ / shares shares
Number of warrants Outstanding beginning balance \| shares	862,500
Number of warrants outstanding ending balance \| shares	862,500
Number of Warrants Exercisable \| shares	862,500
Weighted Average Exercise Price Outstanding balance	$ 3.05
Weighted Average Exercise Price, Granted	0
Weighted Average Exercise Price, Expired/Cancelled	0
Weighted Average Exercise Price, ending balance	3.05
Weighted Average Exercise Price, exercisable	$ 3.05

StockBased Compensation (Deta_2

StockBased Compensation (Details 1)	6 Months Ended
StockBased Compensation (Details 1)	Jun. 30, 2024 USD ($) $ / shares shares
Warrants [Member]
Number Exercisable	862,500
Proceeds to Company if Exercised \| $	$ 2,634,450
Number Outstanding	862,500
Warrant One [Member]
Number Exercisable	448,500
Exercise Price \| $ / shares	$ 2
Proceeds to Company if Exercised \| $	$ 897,000
Weighted Average Remaining Contractual Life (Years)	3 years 11 months 15 days
Number Outstanding	448,500
Warrant Two [Member]
Number Exercisable	54,000
Exercise Price \| $ / shares	$ 3.05
Proceeds to Company if Exercised \| $	$ 164,700
Weighted Average Remaining Contractual Life (Years)	4 years 3 months 3 days
Number Outstanding	54,000
Warrant Three [Member]
Number Exercisable	50,000
Exercise Price \| $ / shares	$ 3.45
Proceeds to Company if Exercised \| $	$ 172,500
Weighted Average Remaining Contractual Life (Years)	1 year 8 months 1 day
Number Outstanding	50,000
Warrants Four [Member]
Number Exercisable	125,000
Exercise Price \| $ / shares	$ 3.95
Proceeds to Company if Exercised \| $	$ 493,750
Weighted Average Remaining Contractual Life (Years)	2 years 6 months 3 days
Number Outstanding	125,000
Warrants Five [Member]
Number Exercisable	185,000
Exercise Price \| $ / shares	$ 4.90
Proceeds to Company if Exercised \| $	$ 906,500
Weighted Average Remaining Contractual Life (Years)	2 years 7 months 2 days
Number Outstanding	185,000

StockBased Compensation (Deta_3

StockBased Compensation (Details 2) - Option [Member]	6 Months Ended
StockBased Compensation (Details 2) - Option [Member]	Jun. 30, 2024 USD ($) $ / shares shares
Number of options outstanding beginning balance \| shares	4,699,569
Number of options, Expired/Cancelled \| $	$ (36,821)
Number of option outstanding ending balance \| shares	4,662,748
Number of options, exercisable \| shares	4,662,748
Weighted Average Exercise Price Outstanding balance	$ 3.87
Weighted Average Exercise Price expires/cancelled	3.40
Weighted Average Exercise Price ending balance	3.88
Weighted Average Exercise Price exercisable balance	$ 3.88

StockBased Compensation (Deta_4

StockBased Compensation (Details 3)	6 Months Ended
StockBased Compensation (Details 3)	Jun. 30, 2024 USD ($) $ / shares shares
Option Six [Member]
Number Exercisable, shares	50,000
Exercise Price \| $ / shares	$ 4.80
Weighted Average Remaining Contractual Life (years)	2 years 6 months 3 days
Proceeds to Company if Exercised \| $	$ 240,000
Number Outstanding, shares	50,000
Option Seven [Member]
Number Exercisable, shares	646,000
Exercise Price \| $ / shares	$ 5
Weighted Average Remaining Contractual Life (years)	2 years 8 months 26 days
Proceeds to Company if Exercised \| $	$ 3,230,000
Number Outstanding, shares	646,000
Options One [Member]
Number Exercisable, shares	585,000
Exercise Price \| $ / shares	$ 3.25
Weighted Average Remaining Contractual Life (years)	7 months 13 days
Proceeds to Company if Exercised \| $	$ 1,901,250
Number Outstanding, shares	585,000
Option Two [Member]
Number Exercisable, shares	944,748
Exercise Price \| $ / shares	$ 3.40
Weighted Average Remaining Contractual Life (years)	7 years 1 month 6 days
Proceeds to Company if Exercised \| $	$ 3,212,143
Number Outstanding, shares	944,748
Option Three [Member]
Number Exercisable, shares	740,000
Exercise Price \| $ / shares	$ 3.60
Weighted Average Remaining Contractual Life (years)	5 years 10 months 9 days
Proceeds to Company if Exercised \| $	$ 2,664,000
Number Outstanding, shares	740,000
Option Four [Member]
Number Exercisable, shares	1,607,837
Exercise Price \| $ / shares	$ 4
Weighted Average Remaining Contractual Life (years)	2 years 2 months 26 days
Proceeds to Company if Exercised \| $	$ 6,431,348
Number Outstanding, shares	1,607,837
Option Five [Member]
Number Exercisable, shares	89,163
Exercise Price \| $ / shares	$ 4.38
Weighted Average Remaining Contractual Life (years)	3 years 6 months 25 days
Proceeds to Company if Exercised \| $	$ 390,534
Number Outstanding, shares	89,163
Total Option [Member]
Number Exercisable, shares	4,662,748
Proceeds to Company if Exercised \| $	$ 18,069,275
Number Outstanding, shares	4,662,748

StockBased Compensation (Deta_5

StockBased Compensation (Details 4) - Stock Options [Member]	6 Months Ended
	Jun. 30, 2024 $ / shares shares
Number Of Rsus Outstanding Begining Balance shares \| shares	3,634,952
Granted \| shares	426,340
Vested/Settled \| shares	(202,261)
Cancelled / Forfeited \| shares	(87,206)
Number Of Rsus Outstanding ending Balance \| shares	3,771,825
Share Price Beginning Balance shares \| $ / shares	$ 1.01
Share Price Granted \| $ / shares	0.72
Share Price Vested/Settled \| $ / shares	2.46
Share Price Cancelled / Forfeited \| $ / shares	1.13
Share Price ending Balance \| $ / shares	$ 0.89

StockBased Compensation (Deta_6

StockBased Compensation (Details 5)	6 Months Ended
StockBased Compensation (Details 5)	Jun. 30, 2024 USD ($) shares
Compensation Expense RSUs \| shares	426,340
RSU Expense \| $	$ 308,810
Compensation Expense One [Member]
Compensation Expense RSUs \| shares	14,000
Equity Incentive Plan	2015
Compensation Expense grant date	Feb. 22, 2024
Compensation Expense Vesting Period	36 Months
First Vesting date	Feb. 22, 2025
RSU Expense \| $	$ 13,589
Second vesting date	Feb. 22, 2026
Third vesting date	Feb. 22, 2027
Compensation Expense Two [Member]
Compensation Expense RSUs \| shares	115,000
Equity Incentive Plan	2015
Compensation Expense grant date	May 23, 2024
Compensation Expense Vesting Period	36 Months
First Vesting date	May 23, 2025
RSU Expense \| $	$ 85,389
Second vesting date	May 23, 2026
Third vesting date	May 23, 2027
Compensation Expense Three [Member]
Compensation Expense RSUs \| shares	297,340
Equity Incentive Plan	2015
Compensation Expense grant date	Jun. 01, 2024
Compensation Expense Vesting Period	11 Months
First Vesting date	May 01, 2025
RSU Expense \| $	$ 209,832

StockBased Compensation (Deta_7

StockBased Compensation (Details 6)	6 Months Ended
StockBased Compensation (Details 6)	Jun. 30, 2024 USD ($) shares
Equity Incentive RSU	202,261
Incentive RSU Issued	153,356
RSUs Held for Taxes \| $	$ 48,905
Equity Incentive RSUD	202,261
Equity Incentive Plan One [Member]
Incentive Plan	2015
Equity Incentive RSU	21,582
Incentive Vest Date	Feb. 08, 2024
Incentive RSU Issued	21,582
RSUs Held for Taxes \| $	$ 0
Equity Incentive Plan Two [Member]
Incentive Plan	2015
Equity Incentive RSU	9,000
Incentive Vest Date	Mar. 01, 2024
Incentive RSU Issued	6,057
RSUs Held for Taxes \| $	$ 2,943
Equity Incentive Plan Three [Member]
Incentive Plan	2015
Equity Incentive RSU	44,217
Incentive Vest Date	Mar. 27, 2024
Incentive RSU Issued	40,530
RSUs Held for Taxes \| $	$ 3,687
Equity Incentive Plan Four [Member]
Incentive Plan	2015
Equity Incentive RSU	51,000
Incentive Vest Date	Apr. 04, 2024
Incentive RSU Issued	32,337
RSUs Held for Taxes \| $	$ 18,663
Equity Incentive Plan Five [Member]
Incentive Plan	2015
Equity Incentive RSU	50,000
Incentive Vest Date	May 01, 2024
Incentive RSU Issued	34,496
RSUs Held for Taxes \| $	$ 15,504
Equity Incentive Plan Six [Member]
Incentive Plan	2015
Equity Incentive RSU	11,500
Incentive Vest Date	Jun. 01, 2024
Incentive RSU Issued	6,670
RSUs Held for Taxes \| $	$ 4,830
Equity Incentive Plan Seven [Member]
Incentive Plan	2015
Equity Incentive RSU	14,962
Incentive Vest Date	Jun. 15, 2024
Incentive RSU Issued	11,684
RSUs Held for Taxes \| $	$ 3,278

StockBased Compensation (Deta_8

StockBased Compensation (Details 7)	6 Months Ended
StockBased Compensation (Details 7)	Jun. 30, 2024 shares
Equity Incentive RSU	202,261
Incentive RSUs Cancelled	87,206
Equity Incentive RSU	87,206
RSUs Cancelled Plan One [Member]
Equity Incentive Plan	2015
Equity Incentive RSU	8,000
Incentive Cancellation Date	Jan. 16, 2024
Incentive Vest Date	Sep. 28, 2024
Incentive RSUs Cancelled	8,000
RSUs Cancelled Plan Two [Member]
Equity Incentive Plan	2015
Equity Incentive RSU	6,000
Incentive Cancellation Date	Jan. 16, 2024
Incentive Vest Date	Oct. 04, 2024
Incentive RSUs Cancelled	6,000
RSUs Cancelled Plan Three [Member]
Equity Incentive Plan	2015
Equity Incentive RSU	8,000
Incentive Cancellation Date	Jan. 16, 2024
Incentive Vest Date	Sep. 28, 2025
Incentive RSUs Cancelled	8,000
RSUs Cancelled Plan Four [Member]
Equity Incentive Plan	2015
Equity Incentive RSU	6,000
Incentive Cancellation Date	Jan. 16, 2024
Incentive Vest Date	Oct. 04, 2025
Incentive RSUs Cancelled	6,000
RSUs Cancelled Plan Five [Member]
Equity Incentive Plan	2015
Equity Incentive RSU	8,000
Incentive Cancellation Date	Jan. 16, 2024
Incentive Vest Date	Sep. 28, 2026
Incentive RSUs Cancelled	8,000
RSUs Cancelled Plan Six [Member]
Equity Incentive Plan	2015
Equity Incentive RSU	667
Incentive Cancellation Date	Feb. 09, 2024
Incentive Vest Date	Jun. 15, 2024
Incentive RSUs Cancelled	667
RSUs Cancelled Plan Seven [Member]
Equity Incentive Plan	2015
Equity Incentive RSU	667
Incentive Cancellation Date	Feb. 09, 2024
Incentive Vest Date	Jun. 15, 2025
Incentive RSUs Cancelled	667
RSUs Cancelled Plan Eight [Member]
Equity Incentive Plan	2015
Equity Incentive RSU	666
Incentive Cancellation Date	Feb. 09, 2024
Incentive Vest Date	Jun. 15, 2026
Incentive RSUs Cancelled	666
RSUs Cancelled Plan Nine [Member]
Equity Incentive Plan	2015
Equity Incentive RSU	1,775
Incentive Cancellation Date	Mar. 25, 2024
Incentive Vest Date	Mar. 27, 2024
Incentive RSUs Cancelled	1,775
RSUs Cancelled Plan Ten [Member]
Equity Incentive Plan	2015
Equity Incentive RSU	2,098
Incentive Cancellation Date	Mar. 25, 2024
Incentive Vest Date	Jun. 15, 2024
Incentive RSUs Cancelled	2,098
RSUs Cancelled Plan Eleven [Member]
Equity Incentive Plan	2015
Equity Incentive RSU	2,667
Incentive Cancellation Date	May 17, 2024
Incentive Vest Date	Oct. 04, 2024
Incentive RSUs Cancelled	2,667
RSUs Cancelled Plan Twelve [Member]
Equity Incentive Plan	2015
Equity Incentive RSU	2,666
Incentive Cancellation Date	May 17, 2024
Incentive Vest Date	Oct. 04, 2025
Incentive RSUs Cancelled	2,666
RSUs Cancelled Plan Thirteen [Member]
Equity Incentive Plan	2015
Equity Incentive RSU	1,000
Incentive Cancellation Date	May 17, 2024
Incentive Vest Date	Mar. 27, 2025
Incentive RSUs Cancelled	1,000
RSUs Cancelled Plan Fourteen [Member]
Equity Incentive Plan	2015
Equity Incentive RSU	1,000
Incentive Cancellation Date	May 17, 2024
Incentive Vest Date	Mar. 27, 2026
Incentive RSUs Cancelled	1,000
RSUs Cancelled Plan Fifteen [Member]
Equity Incentive Plan	2015
Equity Incentive RSU	3,334
Incentive Cancellation Date	May 17, 2024
Incentive Vest Date	Sep. 28, 2024
Incentive RSUs Cancelled	3,334
RSUs Cancelled Plan Sixteen [Member]
Equity Incentive Plan	2015
Equity Incentive RSU	3,333
Incentive Cancellation Date	May 17, 2024
Incentive Vest Date	Sep. 28, 2025
Incentive RSUs Cancelled	3,333
RSUs Cancelled Plan Seventeen [Member]
Equity Incentive Plan	2015
Equity Incentive RSU	3,333
Incentive Cancellation Date	May 17, 2024
Incentive Vest Date	Sep. 28, 2026
Incentive RSUs Cancelled	3,333
RSUs Cancelled Plan Eighteen [Member]
Equity Incentive Plan	2015
Equity Incentive RSU	9,334
Incentive Cancellation Date	May 31, 2024
Incentive Vest Date	Sep. 11, 2024
Incentive RSUs Cancelled	9,334
RSUs Cancelled Plan Nineteen [Member]
Equity Incentive Plan	2015
Equity Incentive RSU	9,333
Incentive Cancellation Date	May 31, 2024
Incentive Vest Date	Sep. 11, 2025
Incentive RSUs Cancelled	9,333
RSUs Cancelled Plan Twenty [Member]
Equity Incentive Plan	2015
Equity Incentive RSU	9,333
Incentive Cancellation Date	May 31, 2024
Incentive Vest Date	Sep. 11, 2026
Incentive RSUs Cancelled	9,333

StockBased Compensation (Deta_9

StockBased Compensation (Details 8)	6 Months Ended
StockBased Compensation (Details 8)	Jun. 30, 2024 $ / shares shares
Option Ten [Member]
Number Of Stock Outstanding Balance	702,654
Share Price \| $ / shares	$ 1.46
Weighted Average Remaining Contractual Life (years)	9 months 3 days
Options One [Member]
Number Of Stock Outstanding Balance	40,000
Share Price \| $ / shares	$ 0.58
Weighted Average Remaining Contractual Life (years)	1 year 4 months 13 days
Option Two [Member]
Number Of Stock Outstanding Balance	450,000
Share Price \| $ / shares	$ 0.68
Weighted Average Remaining Contractual Life (years)	2 years 9 months 18 days
Option Three [Member]
Number Of Stock Outstanding Balance	450,000
Share Price \| $ / shares	$ 0.69
Weighted Average Remaining Contractual Life (years)	1 year 9 months 3 days
Option Four [Member]
Number Of Stock Outstanding Balance	1,535,000
Share Price \| $ / shares	$ 0.70
Weighted Average Remaining Contractual Life (years)	1 year 3 months
Option Five [Member]
Number Of Stock Outstanding Balance	297,340
Share Price \| $ / shares	$ 0.71
Weighted Average Remaining Contractual Life (years)	10 months 2 days
Total Option [Member]
Number Of Stock Outstanding Balance	3,771,825
Option Six [Member]
Number Of Stock Outstanding Balance	115,000
Share Price \| $ / shares	$ 0.74
Weighted Average Remaining Contractual Life (years)	1 year 10 months 24 days
Option Seven [Member]
Number Of Stock Outstanding Balance	14,000
Share Price \| $ / shares	$ 0.97
Weighted Average Remaining Contractual Life (years)	1 year 7 months 24 days
Option Eight [Member]
Number Of Stock Outstanding Balance	6,000
Share Price \| $ / shares	$ 1.31
Weighted Average Remaining Contractual Life (years)	1 year 2 months 12 days
Option Nine [Member]
Number Of Stock Outstanding Balance	14,000
Share Price \| $ / shares	$ 1.32
Weighted Average Remaining Contractual Life (years)	1 year 14 days
Option Eleven [Member]
Number Of Stock Outstanding Balance	17,332
Share Price \| $ / shares	$ 1.58
Weighted Average Remaining Contractual Life (years)	8 months 23 days
Option Twelve [Member]
Number Of Stock Outstanding Balance	12,500
Share Price \| $ / shares	$ 1.69
Weighted Average Remaining Contractual Life (years)	2 months 23 days
Option Thirteen [Member]
Number Of Stock Outstanding Balance	54,333
Share Price \| $ / shares	$ 1.72
Weighted Average Remaining Contractual Life (years)	1 year 2 months 1 day
Option Fourteen [Member]
Number Of Stock Outstanding Balance	29,000
Share Price \| $ / shares	$ 2.01
Weighted Average Remaining Contractual Life (years)	1 month 17 days
Option Fifteen [Member]
Number Of Stock Outstanding Balance	666
Share Price \| $ / shares	$ 2.15
Weighted Average Remaining Contractual Life (years)	11 months 1 day
Option Sixteen [Member]
Number Of Stock Outstanding Balance	34,000
Share Price \| $ / shares	$ 2.95
Weighted Average Remaining Contractual Life (years)	2 months 8 days

StockBased Compensation (Det_10

StockBased Compensation (Details Narrative) - USD ($)	3 Months Ended				6 Months Ended
StockBased Compensation (Details Narrative) - USD ($)	Jun. 30, 2024	Mar. 31, 2024	Jun. 30, 2023	Mar. 31, 2023	Jun. 30, 2024	Jun. 30, 2023
Compensation Expense RSUs					426,340
Share-based Payment Arrangement, Noncash Expense	$ 208,046	$ 411,220	$ 592,174	$ 693,657	$ 619,266	$ 1,285,831
Restricted Stock Units (RSUs) [Member]
Weighted Average Remaining Contractual Life					1 year 4 months 13 days
Compensation Expense RSUs					297,340
Share-based Payment Arrangement, Noncash Expense					$ 614,028	1,030,143
Remaining unrecognized compensation cost related to non-vested RSUs	$ 1,256,598				1,256,598
Option [Member]
Share-based Payment Arrangement, Noncash Expense					$ 0	235,368
Option [Member] \| 2015 Equity Incentive Plan [Member]
Weighted Average Remaining Contractual Life					3 years 8 months 15 days
Common Stock, Shares Authorized	9,700,000				9,700,000
Common Stock Shares Reserved For Future Issuance	354,782				354,782
Warrants [Member]
Weighted Average Remaining Contractual Life					3 years 3 months 29 days
Share-based Payment Arrangement, Noncash Expense					$ 5,238	$ 20,320

Commitments and Contingencies_2

Commitments and Contingencies (Details) - Finance Lease Obligations [Member]	Jun. 30, 2024 USD ($)
2024 - remaining	$ 28,840
2025	57,672
2026	57,661
2027	57,647
2028	57,633
Greater than 5 years	194,395
Total	453,848
Less: Amount representing interest	(42,203)
Present value of minimum lease payments	$ 411,645

Commitments and Contingencies_3

Commitments and Contingencies (Details 1) - USD ($)	6 Months Ended	12 Months Ended
Commitments and Contingencies (Details 1) - USD ($)	Jun. 30, 2024	Dec. 31, 2023
Operating right-of-use assets	$ 512,317	$ 549,504
Operating lease liabilities, current portion	190,099	199,323
Operating lease liabilities, long term	350,810	378,054
Operating Lease Right of Use Obligations [Member]
Operating right-of-use assets	$ 512,317	$ 549,504
Weighted average remaining lease (months)	32 months	33 months
Weighted average discount rate	3.24%	3.02%
Operating lease liabilities, current portion	$ 190,099	$ 199,323
Operating lease liabilities, long term	350,810	378,054
Total operating lease liabilities	$ 540,909	$ 577,377

Commitments and Contingencies_4

Commitments and Contingencies (Details 2) - USD ($)	Jun. 30, 2024	Dec. 31, 2023
Less: imputed interest	$ (1,073,050)
Operating Lease Right of Use Obligations [Member]
2024 - Remaining	117,231
2025	191,273
2026	164,435
2027	92,151
2028	10,212
Total	575,302
Less: imputed interest	(34,393)
Total Operating Lease Liabilities	$ 540,909	$ 577,377

Commitments and Contingencies_5

Commitments and Contingencies (Details 3)	Jun. 30, 2024 USD ($)
Commitments and Contingencies
2024 - Remaining	$ 42,723
2025	7,198
Total Operating Lease Liabilities	$ 49,921

Commitments and Contingencies_6

Commitments and Contingencies (Details 4)	Jun. 30, 2024 USD ($)
Total Grants Repayable	$ 464,108
Grants Repayable [Member]
2024 - Remaining	54,169
2025	36,305
2026	43,756
2027	48,579
2028	51,951
Greater than 5 years	229,348
Total Grants Repayable	$ 464,108

Commitments and Contingencies_7

Commitments and Contingencies (Details 5)	Jun. 30, 2024 USD ($)
Commitments and Contingencies
2024 - Remaining	$ 859,476
2025	1,005,297
2026	781,901
2027	583,641
2028	2,437,212
Greater than 5 years	314,022
Total	5,981,549
Less: imputed interest	(1,073,050)
Total Long-Term Debt	$ 4,908,499

Commitments and Contingencies_8

Commitments and Contingencies (Details 6)	Jun. 30, 2024 USD ($)
Total Amount Remaining	$ 1,343,741
2025 - Estimated	367,808
2024 - Estimated	975,933
National Universty of Taiwan
Total Amount Remaining	510,000
2025 - Estimated	0
2024 - Estimated	510,000
MD Anderson Cancer Center
Total Amount Remaining	449,406
2025 - Estimated	163,546
2024 - Estimated	285,860
Guys and St Thomas
Total Amount Remaining	164,235
2025 - Estimated	102,647
2024 - Estimated	61,588
Xentic Bioscience
Total Amount Remaining	81,447
2025 - Estimated	55,305
2024 - Estimated	26,142
UMC
Total Amount Remaining	138,653
2025 - Estimated	46,310
2024 - Estimated	$ 92,343

Commitments and Contingencies_9

Commitments and Contingencies (Details 7) - Restricted stock option	6 Months Ended
	Jun. 30, 2024 USD ($)
Outstanding Award 3
Outstanding award	$ 527,940
Amortized of outstanding award 2024	0
Amortized of outstanding award 2023	393,853
Amortized of outstanding award 2022	$ 134,087
Vesting period	2023
Unamortized of outstanding award	$ 0
Outstanding Award 4
Outstanding award	517,613
Amortized of outstanding award 2024	126,283
Amortized of outstanding award 2023	260,119
Amortized of outstanding award 2022	$ 65,088
Vesting period	2024
Unamortized of outstanding award	$ 66,123
Outstanding Award 5
Outstanding award	528,864
Amortized of outstanding award 2024	87,894
Amortized of outstanding award 2023	177,584
Amortized of outstanding award 2022	$ 46,686
Vesting period	2025
Unamortized of outstanding award	$ 216,700
Total Member
Outstanding award	1,574,417
Amortized of outstanding award 2024	214,177
Amortized of outstanding award 2023	831,556
Amortized of outstanding award 2022	245,861
Unamortized of outstanding award	$ 282,823

Commitments and Contingencie_10

Commitments and Contingencies (Details 8) - Restricted Stock Options Vested [Member]	6 Months Ended
	Jun. 30, 2024 USD ($)
Total Member
Outstanding award	$ 725,289
Amortized of outstanding award 2024	217,572
Amortized of outstanding award 2023	117,441
Unamortized of outstanding award	390,276
Outstanding Award 1
Outstanding award	$ 241,771
Vesting period	2024
Amortized of outstanding award 2024	$ 118,511
Amortized of outstanding award 2023	63,970
Unamortized of outstanding award	59,290
Outstanding Award 2
Outstanding award	$ 241,764
Vesting period	2025
Amortized of outstanding award 2024	$ 59,416
Amortized of outstanding award 2023	32,071
Unamortized of outstanding award	150,277
Outstanding Award 3
Outstanding award	$ 241,754
Vesting period	2026
Amortized of outstanding award 2024	$ 39,645
Amortized of outstanding award 2023	21,400
Unamortized of outstanding award	$ 180,709

Commitments and Contingencie_11

Commitments and Contingencies (Details Narrative) - USD ($)			6 Months Ended
Commitments and Contingencies (Details Narrative) - USD ($)	Feb. 05, 2024	Nov. 03, 2020	Jun. 30, 2024
Payments For Future Research And Collobration			$ 1,343,741
Total Grants Repayable			464,108
Principal balance payable			163,668
Aggerate Amount Payable, Description		under this agreement will be completed by the end of the third quarter of 2024 at a total additional cost to the Company of up to $0.7 million
Loan agreement, Description	9-month loan agreement with First Insurance Funding for a maximum of $294,603 with fixed interest rate of 8.42%, maturing in November 2024
Total Long-Term Debt			4,908,499
Amount payable for services rendered			146,221
Amount may be payable by Company in future periods for services rendered			363,778
Accrued compensation expense			536,535
Recognized total compensation expense			335,013
RSU 2023 [Member]
Unrecognized compensation expense			390,276
RSU 2024 [Member]
Unrecognized compensation expense			59,290
RSU 2025 [Member]
Unrecognized compensation expense			150,277
RSU 2026 [Member]
Unrecognized compensation expense			180,709
Two Thousand Twenty Two [Member] \| Univercity Of Texas MD [Member]
Collaborative Obligations Amount Due			204,087
Additional Cost Of Company			449,406
Cost			449,406
August Two Thousand Twenty Three [Member] \| Guy's and St Thomas' NHS Foundation Trust [Member]
Collaborative Obligations Amount Due			0
Additional Cost Of Company			164,235
Cost			164,235
July Thirty One Thousand Twenty Three [Member] \| Xenetic Biosciences Inc and CLS Therapeutics [Member]
Collaborative Obligations Amount Due			26,142
Additional Cost Of Company			81,447
Cost			107,589
January TwoThousand Twenty Four [Member] \| University Medical Centre Amsterdam[Member]
Collaborative Obligations Amount Due			46,218
Additional Cost Of Company			138,653
Cost			138,653
Managing Director's Agreement [Member]
Amount payable			209
Royalty Payment			117,761
Clinical Study Research Agreement [Member] \| In 2018 [Member] \| University of Taiwan [Member]
Collaborative Obligations Amount Due			510,000
Collaborative Obligations Amount			$ 25,500
Lease Agreement Expire Period			three-year
Restricted Stock Units (RSUs) [Member]
Recognized total compensation expense			$ 1,291,594
RSU Vested in 2024			451,490
RSU Vested in 2023			527,940
RSU Vested in 2025			312,164
Unrecognized compensation expense			282,823
Operating Lease Right of Use Obligations [Member]
Payment Of Lease Liabilities			125,313
Operating Lease Expense			126,217
Short Term Lease Costs			$ 40,334

Subsequent Events (Details Narr

Subsequent Events (Details Narrative) - USD ($)							3 Months Ended				6 Months Ended
Subsequent Events (Details Narrative) - USD ($)	Aug. 08, 2024	Aug. 04, 2024	Jul. 13, 2024	Jul. 12, 2024	Jul. 08, 2024	Jul. 01, 2024	Jun. 30, 2024	Mar. 31, 2024	Jun. 30, 2023	Mar. 31, 2023	Jun. 30, 2024	Jun. 30, 2023	Jul. 02, 2024	Dec. 31, 2023
Common Stock, Shares Authorized							100,000,000				100,000,000			100,000,000
Common Stock, Shares Par Value							$ 0.001				$ 0.001			$ 0.001
Common Stock, Shares Issued							82,928,314				82,928,314			81,898,321
Share-based Payment Arrangement, Noncash Expense							$ 208,046	$ 411,220	$ 592,174	$ 693,657	$ 619,266	$ 1,285,831
Subsequent Event [Member]
Stock issued during period, shares	9,170,000
Pre-Funded Warrants	3,557,273
Exercise price	$ 0.001
Offering price	$ 0.549
Proceeds from securities	$ 6,400,000
Offering expenses	$ 100,000
Warrants issued to purchase			3,165
Common Stock, Shares Par Value													$ 0.001
Common Stock, Shares Issued													175,000,000
RSUs granted cancelled		46,333		19,666
Common stock, shares withheld for taxes			1,502
RSUs, vested			4,667
Subsequent Event [Member] \| Placement agent[Member]
Warrants issued to purchase	381,818
Subsequent Event [Member] \| Minimum [Member]
Common Stock, Shares Authorized													100,000,000
Subsequent Event [Member] \| Maximum [Member]
Common Stock, Shares Authorized													175,000,000
Subsequent Event [Member] \| July 1, 2024 [Member]
RSUs, vested						38,198
Subsequent Event [Member] \| July 8, 2024 [Member]
RSUs, vested					21,583
Share-based Payment Arrangement, Noncash Expense					$ 13,209
Agreement					RSUs vest upon the achievement of advisory services set out in the agreement with 21,583 vesting on January 1, 2025
Subsequent Event [Member] \| Series A common stock [Member]
Warrants to purchase	12,727,273
Exercise price	$ 0.57
Offering price	$ 0.55
Subsequent Event [Member] \| Series B common stock [Member]
Warrants to purchase	12,727,273
Exercise price	$ 0.57
Offering price	0.55
Subsequent Event [Member] \| Series B common stock [Member] \| Placement agent[Member]
Exercise price	$ 0.6875